Diabetic Nephropathy Market

Diabetic Nephropathy Market Outlook (2023 to 2033)

The Global revenue from the Diabetic Nephropathy was around US$ 2.37 Billion in 2022, with the global market expected to grow at a CAGR of 6.70% to reach a valuation of around US$ 4.86 Billion by the end of 2033.

As assessed by Persistence Market Research, the global diabetic nephropathy market holds nearly 2.0% revenue share of the global renal disease market valued at US$ 120.9 Billion in 2022.

Sales Analysis of Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 7.8% in the last 5 years from 2017 to 2022.

A significant effect of both type 1 and type 2 diabetes is diabetic nephropathy. Diabetic kidney disease is another name for it. The key factor for the market growth is research and development.

• Clinical Trails.gov, in 2021, more than 50 ongoing studies would be related to the treatment for diabetic nephropathy.

The kidneys' abilities to perform their typical function of eliminating redundant materials and surplus fluid from human body is affected by diabetic nephropathy. By maintaining a healthy lifestyle and effectively controlling both diabetes and high blood pressure, diabetic nephropathy can be stopped or delayed.

The rise in the number of senior populations with diabetic nephropathy, the ongoing expansion of the disorders that can be treated with medications for diabetic nephropathy, and the increase in demand for anti-diabetic medications are the main factors driving the diabetic nephropathy market. The market grew as a result of rising testing and incidence rates for various kidney illnesses, both of which are anticipated to present profitable prospects for market growth.

The global market is likely to show high growth over the coming years at a CAGR of 6.70% and reach a global market size of US$ 4.86 Billion by 2033.

How Can the Global Market Grow?

“Rising Prevalence of Diabetic Patients”

There are numerous symptoms of diabetic nephropathy, but the most common is diabetes mellitus. End-stage renal failure is 10 times more common in people with diabetes mellitus.

• International Diabetes Federation (2022) estimates that diabetes was a cause of 6.7 million fatalities in 2021. Similarly, 1 in 10 individuals (20 to 79 years old) have diabetes, which affects 537 million people. By 2030, this figure is expected to reach 643 million, and by 2045, it will reach 783 million.
• According to the International Diabetes Federation (IDF), 40% of diabetics may experience kidney failure in its ultimate stages. Furthermore, about 80% of end-stage renal failure is caused by diabetes and hypertension, either together or individually.

The introduction of new medicine of diabetic nephropathy into developing nations and the drug approvals by FDA is offering a remunerative opportunity to the market.

• For instance, The SGLT2 inhibitor canagliflozin (Invokana, Janssen) received FDA approval for a new use in September 2019 to lower risks for ESRD, worsening renal function, cardiovascular mortality, and heart failure hospitalization among individuals with type 2 diabetes and DKD.

Due to an increase in both temporary and permanent chronic heart disease, hypertensive heart attacks, and diabetic nephropathy, angiotensin-converting enzyme inhibitors are frequently utilized. Thus, it stimulates market expansion.

Can the Market Growth Be Affected in Any Way?

“High Cost of Treatment”

When compared to individuals with diabetes who had no difficulties, it was discovered that people with diabetic kidney disease (DKD) had longer hospital stays and greater medical hospitalization expenditures.

• The estimated price of a patient having DKD was 603 (283-1267) United States Dollars (USD), while the average cost of a DM patient without difficulties was 222 (141-292) USD, according to a paper in NCBI titled Direct medical cost of nephropathy in patients with type 2 diabetes – International Urology and Nephrology Jun 2022.

Likewise, inadequate planning of diabetic nephropathy therapy in low-income countries and a lack of trained experts for treating the condition in rising and less developed nations are the main issues limiting the market.

Also, there is no complete treatment for this illness, and the drugs that are now on the market can only regulate or delay the deterioration of diabetic kidney disease.

Hence, above mentioned reasons will be restraints for the global diabetic nephropathy market.

Country–wise Insights

Why is the United States Market Booming?

"Increased Prevalence of Chronic Kidney Disease (CKD)"

The United States accounted for around 33.7% market share in the global market in 2022.

• According to the Centers for Disease Control and Prevention (CDC) in 2021, CKD was most prevalent in individuals 65 and older (38%), followed by those in their 45s to their 64s (12%), and those in their 18s to their 44s (6%).
• The United States Renal Data System 2020 Annual Data Report estimated that about 786,000 Americans were suffering from end-stage kidney disease (ESKD), commonly referred as end-stage renal disease (ESRD), with 71% receiving dialysis and 29% receiving a kidney transplant.

Poorly managed diabetes leads to the sever conditions like CKD and ESKD which may also cause the diabetic nephropathy. All these factors are driving the market in the country.

What Is the Market Outlook for United Kingdom?

“Developed Guidelines for the Better Treatment and Patient Care”

The United Kingdom market held around 5.4% market share of the global diabetic nephropathy market in 2022.

In 2021, Joint Association of British Clinical Diabetologists and UK Kidney Association guideline offers advice to working clinicians on how to treat hypertension in people with Diabetes Kidney Disease on an individual basis, taking into account factors like age, CKD stage, proteinuria level, and type of diabetes (type I and type II), among others.

These recommendations highlights the value of accurate blood pressure monitoring and measurement, nonpharmacologic management, the use of suitable pharmacologic medicines, and blood pressure objectives based on existing data. Thus, the developed guidelines or policies in the country are raising awareness of diabetic nephropathy, ultimately raising the market.

How is Germany Emerging as a Prominent Market?

“Prevalence of Undiagnosed Early Chronic Kidney Disease”

Germany held a market share of about 6.4% of the market in 2022.

As per Kidney International Reports (2022), a large outpatient database in Germany with patients who met the criteria for an estimated glomerular filtration rate revealed a high rate of undiagnosed early CKD. These findings suggest an opportunity to diagnose CKD earlier and use tailored, evidence-based therapeutics to reduce the risk of disease progression and improve patient outcomes.

Demand for diabetic nephropathy in the country may increase as a result of increased awareness about the rise in CKD diagnosis and the annual decline in kidney function.

What is Market Outlook for China?

"Rising Government Initiatives to Raise Awareness"

The China market held around 4.2% market share of the diabetic nephropathy market in 2022.

Diabetes is becoming more common in China, but knowledge, treatment, and control rates are still low. Death rates, disability rates, and the disease burden from diabetes and its complications are also on the rise, which places a significant cost on individuals, families, and the social economy. For these reasons, the Healthy China Initiative (2019 to 2030) is an initiative to create an innovative public policy structure and a road map for a healthy China. One of the Healthy China Initiative's four preventive and control actions for chronic and non-communicable illnesses is the diabetes prevention and control activity (2019 to 2030). Therefore, such initiatives are aiding in raising public awareness, which is growing the market in the country.

Category–wise Insights

Which Drug Class is Driving Demand within the Global Market?

“Rising Use of Angiotensin Receptor Blockers”

The angiotensin receptor blockers held around 42.3% share of the total market in 2022.

Numerous research point to encouraging developments in therapeutic strategies to stop or slow the evolution of type 2 diabetic nephropathy. The evidence from various research reveal that the antihypertensive angiotensin receptor blockers medicines have a delaying effect on the advancement of diabetic nephropathy and on the formation of proteinuria in type 2 diabetes. ARBs are therefore effective in treating type 2 diabetic nephropathy.

Which Diabetes is Largely Impacted within the Global Market?

“High Incidence of Diabetes Type-II Patients”

Diabetes type-II held around 76.5% share of the total market in 2022.

Diabetes mellitus (DM) is a prominent public health concern and an increasing healthcare challenge globally.

• More than 90% of diabetes diagnoses are type 2, and the number of persons with type 2 diabetes is increasing, though more quickly in low- and middle-income nations than in high-income nations.

The primary cause of end-stage kidney disease (ESKD) and chronic kidney disease (CKD) globally, diabetic kidney disease (DKD) is a significant long-term consequence of diabetes mellitus type 2.

Thus, the rising incidence of diabetes type-II patients may result in diabetic nephropathy which consequently promote the neuropathic pain market.

Which Route of Administration Is Accepted for Diabetic Nephropathy?

“Non-invasiveness, Patient Compliance and Convenience of Drug Administration”

Oral route of administration held around 62.3% share of the total market in 2022.

Oral administration is the most practical, affordable, and well-liked way to provide medication. The drug absorption occurs predominantly in small intestine, and the bioavailability of a medicine depends on how much of the drug is absorbed across the intestinal epithelium. Also even in hospitalized patients with diabetic nephropathy, the oral route was the most commonly prescribed route of drug delivery.

Besides, insulin used orally has the potential to improve insulin portal levels, reduce pain and skin infection risks, and prevent side effects such as hyperinsulinemia, weight gain, and hypoglycemia.

Which Distribution Channel is Widely Adopted for Diabetic Nephropathy?

“To Professionalize the Functioning of the Pharmaceutical Services in Hospitals”

Hospital pharmacies held around 63.1% share of the total market in 2022.

Due to an increase in the number of patients visiting hospitals for diagnosis and treatment, as well as the availability of emergency care facilities and qualified medical personnel. Hospital pharmacies aid in monitoring the receipt and distribution of drugs and medicines, as well as professional supplies, and store and dispense them to inpatients and outpatients. They may also have a manufacturing extension to produce pharmaceuticals and parenteral in bulk.

Competition Landscape

Businesses in this industry are putting money into the research and development of novel medications, and manufacturers place a strong emphasis on providing the greatest number of consumers with distinctive, high quality, and essential healthcare products. Additionally, some businesses are enlarging their market through alliances with other world leaders and mergers and acquisitions.

Some key instances of development include:

• In a joint statement, Boehringer Ingelheim and Eli Lilly and Company claimed that, the United States FDA approved a comparable New Drug Application (sNDA) for empagliflozin tablets registered as Jardiance on January 20, 2023. These tablets have been investigated as a possible therapy to reduce the chance of cardiovascular death and kidney disease progression in adults with CKD.
• On August 26, 2022, Bayer introduced its medication finerenone to India as a treatment for type-2 diabetes and chronic kidney disease (CKD). The medication, hailed as a possible success medicine again for German pharmaceutical company, would be marketed in India as Kerendia.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the diabetic nephropathy, which are available in the full report.

Diabetic Nephropathy Industry Report Scope

Key Segments Covered in Diabetic Nephropathy Industry Research

Drug Class:

• Diuretics
• Angiotensin Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
• Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
• Others

Diabetes Type:

• Type-1 Diabetes
• Type-2 Diabetes

Route of Administration:

• Oral
• Parenteral
• Others

Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

To know more about delivery timeline for this report Contact Sales